Influence of atorvastatin on angiotensin i metabolism in resting and TNF-α -activated rat vascular smooth muscle cells

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 4, 2014, Pages 378-383

  Suski, Maciej ^a   Gębska, Anna ^a   Olszanecki, Rafal ^a   Stachowicz, Aneta ^a   Uracz, Danuta ^a   Madej, Jozef ^a   Korbut, Ryszard ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin; angiotensin converting enzyme; renin; statin; vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ATORVASTATIN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; DIPEPTIDYL CARBOXYPEPTIDASE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PROTEIN METABOLISM; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; REST; WISTAR RAT;

ANGIOTENSIN I; ANIMALS; HEPTANOIC ACIDS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEPRILYSIN; PEPTIDYL-DIPEPTIDASE A; PYRROLES; RATS, WISTAR; REST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918548666     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313475907     Document Type: Article

References (39)

1. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004 ; 84: 767-801
2. Sudano I, Roas S, Noll G. Vascular abnormalities in essential hypertension. Curr Pharm Des. 2011 ; 17: 3039-3044
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 ; 340: 115-126
4. Kumar R, Thomas CM, Yong QC, et al. The intracrine renin-angiotensin system. Clin Sci (Lond). 2012 ; 123: 273-284
5. Nguyen Dinh CA, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides. 2011 ; 32: 2141-2150
6. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension. 2003 ; 42: 574-579
7. Friedrich EB, Clever YP, Wassmann S, et al. Role of integrin-linked kinase in vascular smooth muscle cells: regulation by statins and angiotensin II. Biochem Biophys Res Commun. 2006 ; 349: 883-889
8. Gallagher PE, Ferrario CM, Tallant EA. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol. 2008 ; 295: C1169 - C1174
9. Savoia C, Burger D, Nishigaki N, et al. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011 ; 13: e11
10. Jia G, Stormont RM, Gangahar DM, et al. Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification. Am J Physiol Heart Circ Physiol. 2012 ; 303: H523 - H532
11. Alghamri MS, Weir NM, Anstadt MP, et al. Enhanced angiotensin ii-induced cardiac and aortic remodeling in ACE2 knockout mice. J Cardiovasc Pharmacol Ther. 2012 ;:
12. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005 ; 20: 541-546
13. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy-part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010 ; 44: 241-251
14. Inoue T, Node K. Statin therapy for vascular failure. Cardiovasc Drugs Ther. 2007 ; 21: 281-295
15. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005 ; 5: 579-594
16. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999 ; 147: 253-261
17. Castejon AM, Zollner E, Tristano AG, et al. Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells. J Cardiovasc Pharmacol. 2007 ; 50: 708-711
18. Tristano AG, Castejon AM, Castro A, et al. Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 2007 ; 353: 11-17
19. Chamley-Campbell J, Campbell GR, et al. The smooth muscle cell in culture. Physiol Rev. 1979 ; 59: 1-61
20. Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol. 2012 ; 63: 77-85
21. Andrade BM, Araujo RL, Perry RL, et al. A novel role for AMP-kinase in the regulation of the Na+/I- symporter and iodide uptake in the rat thyroid gland. Am J Physiol Cell Physiol. 2011 ; 300: C1291 - C1297
22. Bujak-Gizycka B, Olszanecki R, Suski M, et al. Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol. 2010 ; 61: 679-682
23. Olszanecki R, Madej J, Suski M, et al. Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol. 2009 ; 60: 191-196
24. Bujak-Gizycka B, Madej J, Wolkow PP, et al. Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). J Physiol Pharmacol. 2007 ; 58: 529-540
25. Coulet F, Gonzalez W, Boixel C, et al. Endothelium-independent conversion of angiotensin I by vascular smooth muscle cells. Cell Tissue Res. 2001 ; 303: 227-234
26. Hayashi N, Yamamoto K, Ohishi M, et al. The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res. 2010 ; 33: 1182-1185
27. Iwai M, Horiuchi M. Devil and angel in the renin- angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009 ; 32: 533-536
28. Akhtar S, Yousif MH, Dhaunsi GS, et al. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol. 2012 ; 165: 1390-1400
29. Sheng-Long C, Yan-Xin W, Yi-Yi H, et al. AVE0991, a nonpeptide compound, attenuates angiotensin ii-induced vascular smooth muscle cell proliferation via induction of heme oxygenase-1 and downregulation of p-38 MAPK phosphorylation. Int J Hypertens. 2012 ; 2012: 958298
30. Yamamoto K, Ohishi M, Ho C, et al. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation. Hypertension. 2009 ; 54: 1353-1359
31. Lee SJ, Kim WJ, Moon SK. TNF-alpha regulates vascular smooth muscle cell responses in genetic hypertension. Int Immunopharmacol. 2009 ; 9: 837-843
32. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009 ; 78: 539-552
33. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010 ; 127: 295-314
34. Saijonmaa O, Nyman T, Fyhrquist F. Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. Am J Physiol Heart Circ Physiol. 2007 ; 292: H1917 - H1921
35. Saijonmaa O, Nyman T, Stewen P, et al. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol. 2004 ; 286: H2096 - H2102
36. Briones AM, Rodriguez-Criado N, Hernanz R, et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension. 2009 ; 54: 142-149
37. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension. 2007 ; 50: 377-383
38. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002 ; 22: 300-305
39. Shyu KG, Chen SC, Wang BW, et al. Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells. Clin Sci (Lond). 2012 ; 122: 33-42